Arrowhead Research Corp PT Raised to $30.00 (ARWR)
Equities researchers at Jefferies Group increased their target price on shares of Arrowhead Research Corp (NASDAQ:ARWR) from $29.00 to $30.00 in a research report issued on Friday. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price suggests a potential upside of 95.19% from the company’s current price.
In other Arrowhead Research Corp news, Director Charles Mckenney unloaded 22,000 shares of the company’s stock on the open market in a transaction dated Monday, June 9th. The stock was sold at an average price of $14.32, for a total value of $315,040.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Arrowhead Research Corp (NASDAQ:ARWR) traded up 10.66% on Friday, hitting $15.37. 3,725,362 shares of the company’s stock traded hands. Arrowhead Research Corp has a 1-year low of $1.81 and a 1-year high of $27.63. The stock’s 50-day moving average is $12.28 and its 200-day moving average is $14.42. The company’s market cap is $797.3 million.
Arrowhead Research Corp (NASDAQ:ARWR) last announced its earnings results on Tuesday, May 6th. The company reported ($0.31) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.20) by $0.11. On average, analysts predict that Arrowhead Research Corp will post $-0.92 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated an “outperform” rating on shares of Arrowhead Research Corp in a research note on Tuesday, May 6th. They now have a $18.75 price target on the stock. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Arrowhead Research Corp in a research note on Monday, March 24th. Six analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $22.91.
Arrowhead Research Corporation (NASDAQ:ARWR) is a biopharmaceutical company developing targeted RNAi therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.